Valeant Stock Surges Ahead of Anticipated Drug Approval

Shares of the Valeant Pharmaceuticals (VRX)  were higher Monday on word the Food and Drug Administration could decide Tuesday on the new drug application of Relistor Oral in the treatment of opioid-induced constipation. Valeant's is expecting a trio of drugs to obtain approval, all by the end of this month, with Rodman & Renshaw projecting roughly $1.5B in new annual sales from the products, giving the debt-laden drug maker some breathing room as maturities loom.

Source:https://www.thestreet.com/video/13643353/valeant-stock-surges-ahead-of-anticipated-drug-approval.html